Literature DB >> 24473180

Symptomatic intracranial hemorrhage after stroke thrombolysis: comparison of prediction scores.

Daniel Strbian1, Patrik Michel, David J Seiffge, Jeffrey L Saver, Heikki Numminen, Atte Meretoja, Kei Murao, Bruno Weder, Nina Forss, Anna-Kaisa Parkkila, Ashraf Eskandari, Charlotte Cordonnier, Stephen M Davis, Stefan T Engelter, Turgut Tatlisumak.   

Abstract

BACKGROUND AND
PURPOSE: Several prognostic scores have been developed to predict the risk of symptomatic intracranial hemorrhage (sICH) after ischemic stroke thrombolysis. We compared the performance of these scores in a multicenter cohort.
METHODS: We merged prospectively collected data of patients with consecutive ischemic stroke who received intravenous thrombolysis in 7 stroke centers. We identified and evaluated 6 scores that can provide an estimate of the risk of sICH in hyperacute settings: MSS (Multicenter Stroke Survey); HAT (Hemorrhage After Thrombolysis); SEDAN (blood sugar, early infarct signs, [hyper]dense cerebral artery sign, age, NIH Stroke Scale); GRASPS (glucose at presentation, race [Asian], age, sex [male], systolic blood pressure at presentation, and severity of stroke at presentation [NIH Stroke Scale]); SITS (Safe Implementation of Thrombolysis in Stroke); and SPAN (stroke prognostication using age and NIH Stroke Scale)-100 positive index. We included only patients with available variables for all scores. We calculated the area under the receiver operating characteristic curve (AUC-ROC) and also performed logistic regression and the Hosmer-Lemeshow test.
RESULTS: The final cohort comprised 3012 eligible patients, of whom 221 (7.3%) had sICH per National Institute of Neurological Disorders and Stroke, 141 (4.7%) per European Cooperative Acute Stroke Study II, and 86 (2.9%) per Safe Implementation of Thrombolysis in Stroke criteria. The performance of the scores assessed with AUC-ROC for predicting European Cooperative Acute Stroke Study II sICH was: MSS, 0.63 (95% confidence interval, 0.58-0.68); HAT, 0.65 (0.60-0.70); SEDAN, 0.70 (0.66-0.73); GRASPS, 0.67 (0.62-0.72); SITS, 0.64 (0.59-0.69); and SPAN-100 positive index, 0.56 (0.50-0.61). SEDAN had significantly higher AUC-ROC values compared with all other scores, except for GRASPS where the difference was nonsignificant. SPAN-100 performed significantly worse compared with other scores. The discriminative ranking of the scores was the same for the National Institute of Neurological Disorders and Stroke, and Safe Implementation of Thrombolysis in Stroke definitions, with SEDAN performing best, GRASPS second, and SPAN-100 worst.
CONCLUSIONS: SPAN-100 had the worst predictive power, and SEDAN constantly the highest predictive power. However, none of the scores had better than moderate performance.

Entities:  

Keywords:  intracranial hemorrhages

Mesh:

Substances:

Year:  2014        PMID: 24473180     DOI: 10.1161/STROKEAHA.113.003806

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  19 in total

1.  TURN: A Simple Predictor of Symptomatic Intracerebral Hemorrhage After IV Thrombolysis.

Authors:  David Asuzu; Karin Nyström; Hardik Amin; Joseph Schindler; Charles Wira; David Greer; Nai Fang Chi; Janet Halliday; Kevin N Sheth
Journal:  Neurocrit Care       Date:  2015-10       Impact factor: 3.210

2.  Cohort-Based Identification of Predictors of Symptomatic Intracerebral Hemorrhage After IV Thrombolysis.

Authors:  David Asuzu; Karin Nyström; Hardik Amin; Joseph Schindler; Charles Wira; David Greer; Nai Fang Chi; Janet Halliday; Kevin N Sheth
Journal:  Neurocrit Care       Date:  2015-12       Impact factor: 3.210

3.  Severe cerebral hypovolemia on perfusion CT and lower body weight are associated with parenchymal haemorrhage after thrombolysis.

Authors:  S Tsetsou; M Amiguet; A Eskandari; R Meuli; P Maeder; B Jiang; M Wintermark; P Michel
Journal:  Neuroradiology       Date:  2016-12-27       Impact factor: 2.804

Review 4.  Update on Neurocritical Care of Stroke.

Authors:  Jason Siegel; Michael A Pizzi; J Brent Peel; David Alejos; Nnenne Mbabuike; Benjamin L Brown; David Hodge; W David Freeman
Journal:  Curr Cardiol Rep       Date:  2017-08       Impact factor: 2.931

5.  Thrombolysis in chinese ischemic stroke patients with renal dysfunction.

Authors:  Wai Ting Lo; Chi Yuen Cheung; Chung Ki Li; Ka Foon Chau; Wing Chi Fong
Journal:  Interv Neurol       Date:  2015-03

6.  Higher neutrophil counts before thrombolysis for cerebral ischemia predict worse outcomes.

Authors:  Ilaria Maestrini; Daniel Strbian; Sophie Gautier; Elena Haapaniemi; Solène Moulin; Tiina Sairanen; Nelly Dequatre-Ponchelle; Gerli Sibolt; Charlotte Cordonnier; Susanna Melkas; Didier Leys; Turgut Tatlisumak; Régis Bordet
Journal:  Neurology       Date:  2015-09-11       Impact factor: 9.910

7.  Comparison of 8 scores for predicting symptomatic intracerebral hemorrhage after IV thrombolysis.

Authors:  David Asuzu; Karin Nystrom; Hardik Amin; Joseph Schindler; Charles Wira; David Greer; Nai Fang Chi; Janet Halliday; Kevin N Sheth
Journal:  Neurocrit Care       Date:  2015-04       Impact factor: 3.210

8.  External validation of the SEDAN score: The real world practice of a single center.

Authors:  Sombat Muengtaweepongsa; Pornpoj Prapa-Anantachai; Pornpatr A Dharmasaroja; Pattarawit Rukkul; Pornchai Yodvisitsak
Journal:  Ann Indian Acad Neurol       Date:  2015 Apr-Jun       Impact factor: 1.383

9.  Paeoniflorin improves functional recovery through repressing neuroinflammation and facilitating neurogenesis in rat stroke model.

Authors:  Hongli Tang; Leiruo Wu; Xixi Chen; Huiting Li; Baojun Huang; Zhenyang Huang; Yiyang Zheng; Liqing Zhu; Wujun Geng
Journal:  PeerJ       Date:  2021-05-28       Impact factor: 2.984

10.  Oxfordshire Community Stroke Project classification improves prediction of post-thrombolysis symptomatic intracerebral hemorrhage.

Authors:  Sheng-Feng Sung; Solomon Chih-Cheng Chen; Huey-Juan Lin; Chih-Hung Chen; Mei-Chiun Tseng; Chi-Shun Wu; Yung-Chu Hsu; Ling-Chien Hung; Yu-Wei Chen
Journal:  BMC Neurol       Date:  2014-03-01       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.